Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease.

Barosi G, Massa M, Campanelli R, Fois G, Catarsi P, Viarengo G, Villani L, Poletto V, Bosoni T, Magrini U, Gale RP, Rosti V.

Leuk Res. 2017 Sep;60:18-23. doi: 10.1016/j.leukres.2017.06.004. Epub 2017 Jun 7.

PMID:
28622624
2.

The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.

Kuo MC, Lin TH, Sun CF, Lin TL, Wu JH, Wang PN, Huang YJ, Chang H, Huang TY, Shih LY.

J Clin Pathol. 2018 Jun;71(6):514-521. doi: 10.1136/jclinpath-2017-204829. Epub 2017 Dec 4.

PMID:
29203554
3.

A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation.

Poletto V, Rosti V, Villani L, Catarsi P, Carolei A, Campanelli R, Massa M, Martinetti M, Viarengo G, Malovini A, Migliaccio AR, Barosi G.

Blood. 2012 Oct 11;120(15):3112-7. doi: 10.1182/blood-2012-05-433466. Epub 2012 Aug 9.

4.

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.

Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, Leone R, Mantovani A, Barbui T, Rambaldi A.

J Hematol Oncol. 2017 Feb 22;10(1):54. doi: 10.1186/s13045-017-0425-z.

5.

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.

Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, Perricone M, Breccia M, Ottaviani E, Testoni N, Merli F, Aversa F, Alimena G, Cavo M, Martinelli G, Catani L, Baccarani M, Vianelli N.

Leukemia. 2015 Jun;29(6):1344-9. doi: 10.1038/leu.2015.87. Epub 2015 Mar 24.

PMID:
25801912
6.

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.

Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E, Pieri L, Pancrazzi A, Ponziani V, Delaini F, Longo G, Ammatuna E, Liso V, Bosi A, Barbui T, Vannucchi AM.

Blood. 2009 Aug 20;114(8):1477-83. doi: 10.1182/blood-2009-04-216044. Epub 2009 Jun 23.

PMID:
19549988
7.

Comparison of JAK2V617F -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.

Latagliata R, Polverelli N, Tieghi A, Palumbo GA, Breccia M, Sabattini E, Villari L, Riminucci M, Valli R, Catani L, Alimena G, Ottaviani E, Fama A, Martinelli G, Perricone M, Spinsanti M, Cavo M, Vianelli N, Palandri F.

Hematol Oncol. 2018 Feb;36(1):269-275. doi: 10.1002/hon.2430. Epub 2017 May 16.

PMID:
28509339
8.

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.

Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, Wu W, Hanson CA, Pardanani A.

Leukemia. 2008 Apr;22(4):756-61. doi: 10.1038/sj.leu.2405097. Epub 2008 Jan 24.

PMID:
18216871
9.

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.

Helbig G, Wieczorkiewicz A, Woźniczka K, Wiśniewska-Piąty K, Rusek A, Kyrcz-Krzemień S.

Med Oncol. 2012 Dec;29(4):2379-84. doi: 10.1007/s12032-012-0190-3. Epub 2012 Mar 1.

PMID:
22383244
10.

Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations.

Li N, Yao QM, Gale RP, Li JL, Li LD, Zhao XS, Jiang H, Jiang Q, Jiang B, Shi HX, Chen SS, Liu KY, Huang XJ, Ruan GR.

Leuk Res. 2015 May;39(5):510-4. doi: 10.1016/j.leukres.2015.02.006. Epub 2015 Feb 19.

PMID:
25746303
11.

Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.

Chen CC, Gau JP, Chou HJ, You JY, Huang CE, Chen YY, Lung J, Chou YS, Leu YW, Lu CH, Lee KD, Tsai YH.

Ann Hematol. 2014 Dec;93(12):2029-36.

PMID:
25015052
12.

Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.

Guo H, Chen X, Tian R, Chang J, Li J, Tan Y, Xu Z, Ren F, Zhao J, Pan J, Zhang N, Wang X, He J, Yang W, Wang H.

PLoS One. 2015 Sep 16;10(9):e0138250. doi: 10.1371/journal.pone.0138250. eCollection 2015. Erratum in: PLoS One. 2015;10(10):e0141173.

13.

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Aug 14;124(7):1062-9. doi: 10.1182/blood-2014-05-578435. Epub 2014 Jul 1.

14.

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.

Yönal İ, Dağlar-Aday A, Akadam-Teker B, Yılmaz C, Nalçacı M, Yavuz AS, Sargın FD.

Turk J Haematol. 2016 Jun 5;33(2):94-101. doi: 10.4274/tjh.2014.0136. Epub 2015 Apr 27.

15.

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.

Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani A.

Leukemia. 2014 Jul;28(7):1472-7. doi: 10.1038/leu.2014.3. Epub 2014 Jan 9.

PMID:
24402162
16.

Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.

Angona A, Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, Camacho L, Fernández-Rodríguez C, Pairet S, Longarón R, Ancochea Á, Senín A, Florensa L, Besses C.

Eur J Haematol. 2015 Mar;94(3):251-7. doi: 10.1111/ejh.12425. Epub 2014 Sep 13.

PMID:
25082530
17.

Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.

Rosti V, Campanelli R, Massa M, Viarengo G, Villani L, Poletto V, Bonetti E, Catarsi P, Magrini U, Grolla AA, Travelli C, Genazzani AA, Barosi G.

Am J Hematol. 2016 Jul;91(7):709-13. doi: 10.1002/ajh.24388. Epub 2016 May 26.

18.

JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.

Barosi G, Poletto V, Massa M, Campanelli R, Villani L, Bonetti E, Viarengo G, Catarsi P, Klersy C, Rosti V.

PLoS One. 2013;8(3):e59791. doi: 10.1371/journal.pone.0059791. Epub 2013 Mar 26.

19.

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.

Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005. Epub 2009 Jul 17.

PMID:
19616600
20.

EZH2 mutational status predicts poor survival in myelofibrosis.

Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T, Winkelman N, Jones AV, Zoi K, Reiter A, Duncombe A, Villani L, Bosi A, Barosi G, Cross NC, Vannucchi AM.

Blood. 2011 Nov 10;118(19):5227-34. doi: 10.1182/blood-2011-06-363424. Epub 2011 Sep 14.

PMID:
21921040

Supplemental Content

Support Center